GE, Affibody align on PET agent targeting breast cancer

GE Healthcare has signed an agreement with Affibody to collaborate on the development of a Her2-targeted PET imaging agent, which is scheduled to begin clinical trials later this year.

Future clinical trials will investigate the confirmation of Her2 status in patients with breast cancer recurrence, to determine if Her2 status changes over time, monitor therapy of patients with metastatic breast cancer receiving anti-Her2 treatments, and help resolve indeterminate Her2 tests, according to the companies. These studies, if positive, could pave the way for better targeting of anti-Her2 therapies to those patients most likely to two.


Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.